These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 30201241)

  • 21. The FDA's patient-focused drug development initiative.
    Kluetz PG; Bhatnagar V
    Clin Adv Hematol Oncol; 2021 Feb; 19(2):70-72. PubMed ID: 33596186
    [No Abstract]   [Full Text] [Related]  

  • 22. Real-world evidence and regulatory drug approval.
    Raphael MJ; Gyawali B; Booth CM
    Nat Rev Clin Oncol; 2020 May; 17(5):271-272. PubMed ID: 32112057
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical and outcome research in oncology. The need for integration.
    Apolone G
    Health Qual Life Outcomes; 2003 Apr; 1():3. PubMed ID: 12713667
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Can disease-free survival be a surrogate for overall survival for drug approvals?
    Marwick C
    J Natl Cancer Inst; 2004 Feb; 96(3):173. PubMed ID: 14759982
    [No Abstract]   [Full Text] [Related]  

  • 25. How should we assess the clinical and cost effectiveness of histology independent cancer drugs?
    Cooper S; Bouvy JC; Baker L; Maignen F; Jonsson P; Clark P; Palmer S; Boysen M; Crabb N
    BMJ; 2020 Jan; 368():l6435. PubMed ID: 31896539
    [No Abstract]   [Full Text] [Related]  

  • 26. The Federal Right to Try Act of 2017-A Wrong Turn for Access to Investigational Drugs and the Path Forward.
    Bateman-House A; Robertson CT
    JAMA Intern Med; 2018 Mar; 178(3):321-322. PubMed ID: 29356821
    [No Abstract]   [Full Text] [Related]  

  • 27. Use of off-label drugs in cancer care again under review.
    Braud E; Downs CG
    ONS News; 2005 Mar; 20(3):8. PubMed ID: 15794064
    [No Abstract]   [Full Text] [Related]  

  • 28. Recasting cancer trials.
    Nat Biotechnol; 2012 Jul; 30(7):567. PubMed ID: 22781659
    [No Abstract]   [Full Text] [Related]  

  • 29. Use, Safety, and Efficacy of Single-Patient Use of the US Food and Drug Administration Expanded Access Program.
    Feit NZ; Goldman DA; Smith E; Deighan J; Iasonos A; Zivanovic O; Hyman DM
    JAMA Oncol; 2019 Apr; 5(4):570-572. PubMed ID: 30816938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessing tumor-related signs and symptoms to support cancer drug approval.
    Williams G; Pazdur R; Temple R
    J Biopharm Stat; 2004 Feb; 14(1):5-21. PubMed ID: 15027497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Approvals in 2018: a histology-agnostic new molecular entity, novel end points and real-time review.
    Blumenthal GM; Pazdur R
    Nat Rev Clin Oncol; 2019 Mar; 16(3):139-141. PubMed ID: 30670830
    [No Abstract]   [Full Text] [Related]  

  • 32. The Timing of Cancer Drug Approvals in the United States and Europe.
    Jenei K
    JAMA Netw Open; 2022 Jun; 5(6):e2216191. PubMed ID: 35687342
    [No Abstract]   [Full Text] [Related]  

  • 33. Accelerated approvals hit the target in precision oncology.
    Subbiah V; Wirth LJ; Kurzrock R; Pazdur R; Beaver JA; Singh H; Mehta GU
    Nat Med; 2022 Oct; 28(10):1976-1979. PubMed ID: 36192554
    [No Abstract]   [Full Text] [Related]  

  • 34. Approvals in 2021: dangling Accelerated Approvals, drug dosing, new approvals and beyond.
    Lemery S; Pazdur R
    Nat Rev Clin Oncol; 2022 Apr; 19(4):217-218. PubMed ID: 35136230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. White House announces cancer-drug initiatives.
    Am J Health Syst Pharm; 1996 May; 53(10):1110. PubMed ID: 8734669
    [No Abstract]   [Full Text] [Related]  

  • 36. The ODAC Chronicles: Part 4. Hurdles pre and post accelerated approval.
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2005 Apr; 5(2):197-200. PubMed ID: 15877516
    [No Abstract]   [Full Text] [Related]  

  • 37. Expensive cancer therapies: unintended effects.
    Delude CM
    J Natl Cancer Inst; 2015 Jan; 107(1):497. PubMed ID: 25564602
    [No Abstract]   [Full Text] [Related]  

  • 38. Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals.
    Kim C; Prasad V
    JAMA Intern Med; 2015 Dec; 175(12):1992-4. PubMed ID: 26502403
    [No Abstract]   [Full Text] [Related]  

  • 39. The seamless approach to drug development in oncology.
    Pazdur R
    Clin Adv Hematol Oncol; 2016 Dec; 14(12):958-959. PubMed ID: 28212356
    [No Abstract]   [Full Text] [Related]  

  • 40. Evaluation and Regulation of Oncology Drug Approval: Finding the Right Balance.
    Lyman GH
    JAMA Oncol; 2016 Jun; 2(6):728-9. PubMed ID: 26939751
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.